Showing papers by "Beat Müllhaupt published in 2012"
French Institute of Health and Medical Research1, Paris Descartes University2, University of Lausanne3, Swiss Institute of Bioinformatics4, University of Paris5, Rockefeller University6, University of Zurich7, University of St. Gallen8, University of Bern9, University Hospital of Basel10, University Hospital of Lausanne11, University of Sydney12, Cornell University13, Pierre-and-Marie-Curie University14, Geneva College15
TL;DR: The GWA study identified several susceptibility loci for HCV-induced liver fibrosis linked to genes that regulate apoptosis; these were linked to factors involved in phagocytosis of apoptotic cells by macrophages.
147 citations
TL;DR: A comprehensive model to predict outcome after liver transplantation, with a novel focus on the impact of the presence of steatosis in the graft, found that microsteatosis, regardless of the amount, was associated with a similar relationship between mortality and BAR score as nonsteatotic livers.
Abstract: OBJECTIVE:
To integrate the amount of hepatic steatosis in modern liver allocation models.
BACKGROUND:
The aim of this study was to combine the 2 largest liver transplant databases (United States and Europe) in 1 comprehensive model to predict outcome after liver transplantation, with a novel focus on the impact of the presence of steatosis in the graft.
METHODS:
We adjusted the balance of risk (BAR) score for its application to the European Liver Transplant Registry (ELTR) database containing 11,942 patients. All liver transplants from ELTR and United Network for Organ Sharing with recorded liver biopsies were then combined in one survival analysis in relation to the presence of graft micro- (n = 9,677) and macrosteatosis (n = 11,516).
RESULTS:
Microsteatosis, regardless of the amount, was associated with a similar relationship between mortality and BAR score as nonsteatotic livers. Low-grade macrosteatotic liver grafts (≤30% macrosteatosis) resulted in 5-year graft-survival rates of 60% or more up to BAR 18, comparable to nonsteatotic grafts. However, use of moderate or severely steatotic liver grafts (>30% macrosteatosis) resulted in acceptable outcome only if the cumulative risk at transplant was low, that is, BAR score of 9 or less.
CONCLUSIONS:
Microsteatotic or 30% or less macrosteatotic liver grafts can be used safely up to BAR score of 18 or less, but liver grafts with more than 30% macrosteatotis should be used with risk adjustment, that is, up to BAR score of 9 or less.
147 citations
University of Lausanne1, Swiss Institute of Bioinformatics2, French Institute of Health and Medical Research3, Paris Descartes University4, University of Zurich5, University of St. Gallen6, University Hospital of Basel7, University of Bern8, Pierre-and-Marie-Curie University9, Rockefeller University10
TL;DR: In chronic hepatitis C, IL28B variants associated with poor response to interferon therapy may predict slower fibrosis progression, especially in patients infected with non‐1 HCV genotypes.
142 citations
TL;DR: Decreased vitamin D levels have been described in various forms of chronic liver disease and associated with advanced fibrosis, and whether this association is a cause or consequence ofAdvanced fibrosis remains unclear.
Abstract: Decreased vitamin D levels have been described in various forms of chronic liver disease and associated with advanced fibrosis. Whether this association is a cause or consequence of advanced fibrosis remains unclear to date.
99 citations
67 citations
TL;DR: In patients with CHC, elevated serum ferritin levels are independently associated with advanced liver fibrosis, hepatic steatosis, and poor response to interferon‐alpha‐based therapy.
44 citations
TL;DR: Different metacestode-derived antigens of E. granulosus and E. multilocularis are valuable, widely accessible, and cost-efficient tools for the serological diagnosis of echinococcosis, however, confirmatory testing is necessary, due to the lack of species specificity and the occurrence of cross-reactions to other helminthic diseases.
Abstract: Purpose
Human alveolar (AE) and cystic echinococcosis (CE) caused by the metacestode stages of Echinococcus multilocularis and E. granulosus, respectively, lack pathognomonic clinical signs. Diagnosis therefore relies on the results of imaging and serological studies. The primary goal of this study was to evaluate the efficacy of several easy-to-produce crude or partially purified E. granulosus and E. multilocularis metacestode-derived antigens as tools for the serological diagnosis and differential diagnosis of patients suspicious for AE or CE.
43 citations
TL;DR: Sorafenib initially promotes necrosis after RFA in liver tissue, but the delay in tissue repair is overcome at day 7 presumably by transient compensatory overexpression of growth signals.
26 citations
TL;DR: C5 deficiency leads to attenuated inflammation and normalized MMP-9 activity concomitantly with a significant reduction of fibrosis, and appears to be an attractive target for future therapeutic intervention in chronic cholestatic liver disease.
25 citations
TL;DR: Beside the expected characteristics (age, gender, cirrhosis, alcohol), these data stress the role of diabetes mellitus and reveal the importance of low socioeconomic status as a risk factor for HCC in Swiss patients infected with hepatitis C virus.
Abstract: Hepatocellular carcinoma (HCC) is the most frequent form of primary liver cancer and chronic infection with hepatitis C virus is one of the main risk factors for HCC. This study analyses the characteristics of the patients with chronic hepatitis C participating in the Swiss Hepatitis C Cohort Study who developed HCC.
17 citations
TL;DR: The present expert opinion statement by the Swiss Association for the Study of the Liver shall provide guidance on the treatment of chronic hepatitis C with triple therapy comprising telaprevir or boceprevir.
Abstract: Hepatitis C virus (HCV) infection is a leading cause of chronic hepatitis, liver cirrhosis and hepatocellular carcinoma worldwide Two first-generation protease inhibitors, telaprevir and boceprevir, have recently been approved for the treatment of chronic hepatitis C genotype 1 Triple therapy comprising pegylated interferon-α, ribavirin and telaprevir or boceprevir increases sustained virological response rates to ~70% and allows to shorten treatment duration in ~½ of treatment-naive patients with chronic hepatitis C genotype 1 Sustained virological response rates in treatment-experienced patients depend on the response to previous treatment, ranging from <80% in previous relapsers to ~30% in previous null responders These advances come at the expense of new adverse effects and increased cost In addition, treatment of chronic hepatitis C will become more complex In these times of changing medical practice, the present expert opinion statement by the Swiss Association for the Study of the Liver shall provide guidance on the treatment of chronic hepatitis C with triple therapy comprising telaprevir or boceprevir
TL;DR: It is concluded that ABCB11 and NR1I1 polymorphisms are obviously not associated with development of cirrhosis in patients with ALD.
Abstract: Increased serum bile salt levels have been associated to a single-nucleotide polymorphism in the bile salt export pump (BSEP; ABCB11) in several acquired cholestatic liver diseases but there is little evidence in alcoholic liver disease (ALD). Furthermore, a crosstalk between vitamin D and bile acid synthesis has recently been discovered. Whether this crosstalk has an influence on the course of ALD is unclear to date. Our aim was to analyse the role of genetic polymorphisms in BSEP and the vitamin D receptor gene (NR1I1) on the emergence of cirrhosis in patients with ALD. Therefore, 511 alcoholic patients (131 with cirrhosis and 380 without cirrhosis) underwent ABCB11 genotyping (rs2287622). Of these, 321 (131 with cirrhosis and 190 without cirrhosis) were also tested for NR1I1 polymorphisms (bat-haplotype: BsmI rs1544410, ApaI rs7975232 and TaqI rs731236). Frequencies of ABCB11 and NR1I1 genotypes and haplotypes were compared between alcoholic patients with and without cirrhosis and correlated to serum bile salt, bilirubin and aspartate aminotransferase levels in those with cirrhosis. Frequencies of ABCB11 and NR1I1 genotypes and haplotypes did not differ between the two subgroups and no significant association between genotypes/haplotypes and liver function tests could be determined for neither polymorphism. We conclude that ABCB11 and NR1I1 polymorphisms are obviously not associated with development of cirrhosis in patients with ALD.
28 Mar 2012
TL;DR: Therapieoptionen haben sich mit der Etablierung neuer interventioneller Verfahren und einer systemisch wirksamen Therapie deutlich erweitert, bei der neben Tumorcharakteristika auch Leberfunktion und Allgemeinzustand berücksichtigt werden.
Abstract: ZusammenfassungFür eine möglichst frühe Diagnostik des Leberzellkarzinoms wurden bei Patienten mit Leberzirrhose in den letzten Jahren nicht invasive bildgebende Diagnosekriterien festgelegt. Zum Staging hat sich die BCLC-Klassifikation etabliert, bei der neben Tumorcharakteristika auch Leberfunktion und Allgemeinzustand berücksichtigt werden. Die Therapieoptionen haben sich mit der Etablierung neuer interventioneller Verfahren und einer systemisch wirksamen Therapie deutlich erweitert.
TL;DR: In this paper, die BCLC-Klassifikation etabliert, bei der neben Tumorcharakteristika auch Leberfunktion und Allgemeinzustand beruckichtigt werden.
Abstract: Fur eine moglichst fruhe Diagnostik des Leberzellkarzinoms wurden bei Patienten mit Leberzirrhose in den letzten Jahren nicht invasive bildgebende Diagnosekriterien festgelegt. Zum Staging hat sich die BCLC-Klassifikation etabliert, bei der neben Tumorcharakteristika auch Leberfunktion und Allgemeinzustand berucksichtigt werden. Die Therapieoptionen haben sich mit der Etablierung neuer interventioneller Verfahren und einer systemisch wirksamen Therapie deutlich erweitert.
28 Mar 2012